Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1/Phase 2
PRINCE trial: what clinicians have said so far
PRINCE (PSMA-lutetium Radionuclide Therapy and ImmuNotherapy in Prostate CancEr)
- NCT03658447 ↗
- Completed
- Peter MacCallum Cancer Centre, Australia
- Focused size, estimated: 1–150 verified statements once built
We haven't built an HCP commentary report on PRINCE (metastatic castration resistant prostate cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on PRINCE so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 3 posts on X, typically up to 13 once built |
The trial
ClinicalTrials.gov- Official title
- Phase Ib/II Study of Radionuclide 177Lutetium-PSMA-617 Therapy in Combination With Pembrolizumab for Treatment of Metastatic Castration Resistant Prostate Cancer (mCRPC)
- Phase
- Phase 1/Phase 2
- Status
- Completed
- Conditions
- Metastatic Castration Resistant Prostate Cancer
- Interventions
- Pembrolizumab; 177Lu-PSMA
- Arms
- 177Lu-PSMA + Pembrolizumab · Experimental
- Enrollment
- 37
- Primary outcomes
- Prostate Specific Antigen (PSA) response
- Incidence of Treatment-Emergent Adverse Events [Safety]
- Tolerability
- Sponsor
- Peter MacCallum Cancer Centre, Australia
- Start
- Jul 12, 2019
- Primary completion
- Dec 22, 2022
- Results posted
- No
- Registry record
- NCT03658447 · updated Jul 28, 2023
Publications
linked from the registry- Sandhu S, Joshua AM, Emmett L, Bressel M, Anton A, Spain L, Horvath LG, Pasam A, Tolmeijer SH, Akhurst TJ, Alipour R, Banks P, Buteau JP, Cassidy E, Crumbaker M, Dhiantravan N, Xu W, Chan J, Hitchen N, Scalzo M, Ravi Kumar AS, Kong G, Wallace R, Williams N, Williams S, Haynes NM, Neeson P, Wyatt AW, Hicks RJ, Hofman MS. [177Lu]Lu-PSMA-617 in combination with pembrolizumab for treatment of metastatic castration resistant prostate cancer (PRINCE): a single-arm, phase 1b/2 study. Lancet Oncol. 2026 Apr;27(4):470-479. doi: 10.1016/S1470-2045(26)00017-3. PubMed 41926961
- Kashyap R, Buteau JP, Bressel M, Eifer M, Bollampally N, Jackson P, McIntosh L, Sandhu S, Hofman MS. Prognostic Value of Posttherapy SPECT/CT for Overall Survival in Patients Undergoing [177Lu]Lu-PSMA-617 Radiopharmaceutical Therapy: Results from 3 Clinical Trials. J Nucl Med. 2025 Aug 1;66(8):1265-1270. doi: 10.2967/jnumed.125.269640. PubMed 40610228